HemoShear Therapeutics CEO and leadership

James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization of more than 3,000 employees. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. Powers was an advisor to the Coulter Translational Research Partnership in Biomedical Engineering at the University of Virginia where he met Drs. Blackman and Wamhoff. Powers currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Powers received a BS in Administration and Management Science from Carnegie-Mellon University.

Blackman, Vice President and Chief Scientific Officer of the Company, is co-inventor of the HemoShear technology and co-founder of HemoShear. He is responsible for scientific development of HemoShear’s commercial relationships. Prior to HemoShear, he was a tenured associate professor in the Department of Biomedical Engineering at the University of Virginia (U.Va.). At U.Va., Dr. Blackman’s lab made fundamental advances in uncovering the importance of hemodynamics and biological transport in atherosclerosis-based diseases and has made numerous novel scientific discoveries in vascular cell biology. Blackman also served in leadership positions with U.Va.’s School of Engineering and Sciences Dean’s Research Advisory Committee, the Robert M. Berne Cardiovascular Research Center and the American Heart Association Bioengineering & Biotechnology study section. Blackman trained as a postdoctoral research fellow in the Vascular Research Division, Department of Pathology of Brigham & Women’s Hospital and Harvard Medical School. He obtained a BS in mechanical engineering from Drexel University and a PhD in bioengineering from the University of Pennsylvania. Blackman currently holds the academic position of adjunct associate professor of biomedical engineering at U.Va.

Wamhoff is co-founder of HemoShear and co-inventor of its technology. Wamhoff is an associate professor at the University of Virginia (UVa) and leads an NIH-funded laboratory that studies vascular disease at the Cardiovascular Division of UVa’s Department of Medicine. Wamhoff began his fellowship at UVa developing rodent models to investigate the molecular mechanisms of genes underlying vascular disease. Wamhoff was also employed by Setagon, Inc. as lead scientist to develop a novel drug-eluting stent for the treatment of blood vessel stenosis in humans. During his UVa tenure Wamhoff has obtained several million dollars in funding from Pfizer, the American Heart Association, NIH, and other organizations to study the fundamental mechanisms that regulate smooth muscle cell phenotypic switching in vascular disease, these efforts resulted in over fifteen patent filings. Wamhoff has authored or co-authored 42 articles, three book chapters, and four commentaries. Wamhoff serves as peer reviewer for more than fifteen major scientific journals and is a grant reviewer for the American Heart Association. Wamhoff has also received multiple awards, including the Robert M. Berne Trainee Achievement Award, the American Physiological Society Young Cardiovascular Investigator Award, the 2008 Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Irvine Paige Award, and the 2010 American Physiological Society New Investigator Award for Cardiovascular Research. Wamhoff obtained a B.S. in Biology with a minor in Business Administration from Rhodes College and obtained his PhD from the University of Missouri, where he developed swine models of diabetes and atherosclerosis. Wamhoff devotes philanthropic time to the community by promoting health awareness for the American Heart Association.

Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President of their Washington office in 1973. In 1977, Campbell co-founded Midway Airlines, Inc., the first new start-up carrier after airline deregulation, where he served as CFO and participated in the raising of venture capital to fund the airline’s launch. Campbell returned to the aviation consulting business in 1983 and is currently chairman of The Campbell-Hill Aviation Group in Alexandria, VA. Campbell has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. Campbell currently serves as vice chairman and acting CFO of Dynamic Literacy, LLC, advisor to Targeson, LLC, a University of Virginia (UVa)-based biotechnology company, advisor and investor in BioMotion Analytics, LLC, is a member of the advisory board of UVa’s Heart and Vascular Center, and serves on the UVa Patent Foundation Advisory Panel. Campbell earned a Bachelor of Commerce from McGill University, an MBA from the University of Western Ontario, and a PhD in Business Administration from Columbia University.

Aric Holsinger brings 20 years of CFO experience from the telecommunications, technology and professional sports industries. Prior to joining ePals, Holsinger was CFO for Critical RF, a provider of interoperability solutions linking smartphones, computers and two-way radio systems. Prior to that, Holsinger was CFO for MCT, a wireless communications provider with operations in Russian and Central Asia where he led the growth from its start-up phase to a $300M sale to TeliaSonera. Holsinger joined MCT following CFO positions with the Baltimore Orioles and the Baltimore Stallions, a Canadian League Football team. He began his career with Arthur Andersen, specializing in the high tech and emerging growth companies. Holsinger holds a BS in Accounting and Management Information Systems from the University of Virginia.

Brian Johns is a Chief Scientific Officer at Hemoshear and is based in Charlottesville Virginia Area. He has worked as VP HIV DPU at GSK; Vice President at ViiV Healthcare; and Director, HIV Medicinal Chemistry at GSK. Brian studied at Andrews University between 1989 and 1993, University of Virginia between 1997 and 1999, and Wayne State University between 1993 and 1997.

Blackman, Vice President and Chief Scientific Officer of the Company, is co-inventor of the HemoShear technology and co-founder of HemoShear. He is responsible for scientific development of HemoShear’s commercial relationships. Prior to HemoShear, he was a tenured associate professor in the Department of Biomedical Engineering at the University of Virginia (U.Va.). At U.Va., Dr. Blackman’s lab made fundamental advances in uncovering the importance of hemodynamics and biological transport in atherosclerosis-based diseases and has made numerous novel scientific discoveries in vascular cell biology. Blackman also served in leadership positions with U.Va.’s School of Engineering and Sciences Dean’s Research Advisory Committee, the Robert M. Berne Cardiovascular Research Center and the American Heart Association Bioengineering & Biotechnology study section. Blackman trained as a postdoctoral research fellow in the Vascular Research Division, Department of Pathology of Brigham & Women’s Hospital and Harvard Medical School. He obtained a BS in mechanical engineering from Drexel University and a PhD in bioengineering from the University of Pennsylvania. Blackman currently holds the academic position of adjunct associate professor of biomedical engineering at U.Va.

Wamhoff is co-founder of HemoShear and co-inventor of its technology. Wamhoff is an associate professor at the University of Virginia (UVa) and leads an NIH-funded laboratory that studies vascular disease at the Cardiovascular Division of UVa’s Department of Medicine. Wamhoff began his fellowship at UVa developing rodent models to investigate the molecular mechanisms of genes underlying vascular disease. Wamhoff was also employed by Setagon, Inc. as lead scientist to develop a novel drug-eluting stent for the treatment of blood vessel stenosis in humans. During his UVa tenure Wamhoff has obtained several million dollars in funding from Pfizer, the American Heart Association, NIH, and other organizations to study the fundamental mechanisms that regulate smooth muscle cell phenotypic switching in vascular disease, these efforts resulted in over fifteen patent filings. Wamhoff has authored or co-authored 42 articles, three book chapters, and four commentaries. Wamhoff serves as peer reviewer for more than fifteen major scientific journals and is a grant reviewer for the American Heart Association. Wamhoff has also received multiple awards, including the Robert M. Berne Trainee Achievement Award, the American Physiological Society Young Cardiovascular Investigator Award, the 2008 Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Irvine Paige Award, and the 2010 American Physiological Society New Investigator Award for Cardiovascular Research. Wamhoff obtained a B.S. in Biology with a minor in Business Administration from Rhodes College and obtained his PhD from the University of Missouri, where he developed swine models of diabetes and atherosclerosis. Wamhoff devotes philanthropic time to the community by promoting health awareness for the American Heart Association.

James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization of more than 3,000 employees. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. Powers was an advisor to the Coulter Translational Research Partnership in Biomedical Engineering at the University of Virginia where he met Drs. Blackman and Wamhoff. Powers currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Powers received a BS in Administration and Management Science from Carnegie-Mellon University.

Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President of their Washington office in 1973. In 1977, Campbell co-founded Midway Airlines, Inc., the first new start-up carrier after airline deregulation, where he served as CFO and participated in the raising of venture capital to fund the airline’s launch. Campbell returned to the aviation consulting business in 1983 and is currently chairman of The Campbell-Hill Aviation Group in Alexandria, VA. Campbell has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. Campbell currently serves as vice chairman and acting CFO of Dynamic Literacy, LLC, advisor to Targeson, LLC, a University of Virginia (UVa)-based biotechnology company, advisor and investor in BioMotion Analytics, LLC, is a member of the advisory board of UVa’s Heart and Vascular Center, and serves on the UVa Patent Foundation Advisory Panel. Campbell earned a Bachelor of Commerce from McGill University, an MBA from the University of Western Ontario, and a PhD in Business Administration from Columbia University.